Literature DB >> 3335167

Reversibility of airway obstruction in relation to prognosis in chronic obstructive pulmonary disease.

Y Kawakami1, F Kishi, K Dohsaka, Y Nishiura, A Suzuki.   

Abstract

Whether reversibility in airway obstruction with beta-adrenergic stimulant is a significant determinant for the outcome was tested in 59 patients with pulmonary emphysema and chronic bronchitis. During four years of follow-up, 43 (73 percent) patients survived and 16 (27 percent) died. Initial VC. FVC, FEV1, and PaO2 were significantly smaller, and PaCO2 was significantly larger in nonsurvivors than those in survivors. After orciprenaline sulfate (10 mg in 0.5 ml solution) inhalation, VC and FEV1 increased in comparable amount between the two groups. Airway reversibility as estimated by percentage changes in FEV1 before and after the bronchodilator (reversibility index) was similar between the two groups. In the 16 nonsurvivors, hypoxemic patients had similar FEV1, FEV1/FVC, and reversibility indices as normoxemic patients. These results indicate that not airway reversibility per se but a fixed or irreversible component of airway obstruction is one of the determinants of the prognosis in pulmonary emphysema and chronic bronchitis. Chronic hypoxemia is related to neither airway obstruction nor its reversibility, while it does influence the prognosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3335167     DOI: 10.1378/chest.93.1.49

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  2 in total

1.  Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group.

Authors:  P L Brand; P H Quanjer; D S Postma; H A Kerstjens; G H Koëter; P N Dekhuijzen; H J Sluiter
Journal:  Thorax       Date:  1992-06       Impact factor: 9.139

2.  Importance of slow vital capacity in the detection of airway obstruction.

Authors:  Ana Raquel Gonçalves de Barros; Margarida Batista Pires; Nuno Miguel Ferreira Raposo
Journal:  J Bras Pneumol       Date:  2013 May-Jun       Impact factor: 2.624

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.